Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/13355
Full metadata record
DC FieldValueLanguage
dc.contributor.authorYoung, N Ren
dc.contributor.authorBaker, H Wen
dc.contributor.authorLiu, Gen
dc.contributor.authorSeeman, Egoen
dc.date.accessioned2015-05-16T03:11:28Z
dc.date.available2015-05-16T03:11:28Z
dc.date.issued1993-10-01en
dc.identifier.citationThe Journal of Clinical Endocrinology and Metabolism; 77(4): 1028-32en
dc.identifier.govdoc8408450en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/13355en
dc.description.abstractTo determine the effect of androgens on body composition and muscle strength, we measured fat-free mass (kg), fat mass (kg), and bone density (g/cm2) by dual x-ray absorptiometry, and muscle strength (Newton meters) by dynamometry in a controlled, prospective study involving 13 nonathletic men receiving testosterone enanthate 200 mg/week in for 6 months and 8 healthy controls. Biochemical markers of bone turnover were measured in the treated subjects at baseline and 6 months. In the treated subjects at 6 months, fat-free mass (mean +/- SEM) increased by 9.6 +/- 1.0% (P < or = 0.01) whereas fat mass decreased by 16.2 +/- 6.7% (P < or = 0.05). Changes in muscle strength ranged from -1.6-19.2%. Only hip adduction increased 19.2 +/- 9.5% (P < 0.05). Changes in bone density ranged from -1.3-5.2%, decreasing significantly at one site and increasing significantly at four of the nine sites measured (P < 0.05). Serum testosterone increased by 91.1 +/- 7.5% (P < 0.01), and testicular volume decreased by 24.0 +/- 3.2% (P < 0.01). Serum osteocalcin increased by 35.7 +/- 17.3% (P < 0.05), serum immunoreactive PTH (iPTH) increased by 41.4 +/- 15.1% (P < 0.05), serum calcium decreased by 2.3 +/- 1.0% (P < 0.05), and serum albumin decreased by 4.5 +/- 1.7% (P < 0.05). There were no detectable changes in fat-free mass, fat mass, muscle strength, or bone density in controls. The administration of testosterone enanthate in pharmacological doses for 6 months resulted in a modest reduction in fat mass and small increases in fat-free mass, muscle strength, and bone density. These changes do not support the use of androgens for enhancing athletic performance.en
dc.language.isoenen
dc.subject.otherAndrogensen
dc.subject.otherBiologyen
dc.subject.otherBody Weight--changesen
dc.subject.otherCase Control Studiesen
dc.subject.otherContraceptionen
dc.subject.otherContraceptive Agentsen
dc.subject.otherContraceptive Agents, Maleen
dc.subject.otherEndocrine Systemen
dc.subject.otherExaminations And Diagnosesen
dc.subject.otherFamily Planningen
dc.subject.otherHematological Effectsen
dc.subject.otherHemic Systemen
dc.subject.otherHormonesen
dc.subject.otherLaboratory Examinations And Diagnosesen
dc.subject.otherLaboratory Proceduresen
dc.subject.otherPhysiologyen
dc.subject.otherProspective Studiesen
dc.subject.otherResearch Reporten
dc.subject.otherSerum Calcium Levelen
dc.subject.otherSerum Protein Effectsen
dc.subject.otherSpermatogenesis Blocking Agentsen
dc.subject.otherStudiesen
dc.subject.otherTestosteroneen
dc.subject.otherAbsorptiometry, Photonen
dc.subject.otherAdulten
dc.subject.otherAlkaline Phosphatase.blooden
dc.subject.otherBiological Markersen
dc.subject.otherBody Composition.drug effectsen
dc.subject.otherBone Density.drug effectsen
dc.subject.otherCalcium.blooden
dc.subject.otherContraceptive Agents, Male.pharmacokinetics.pharmacologyen
dc.subject.otherCreatinine.urineen
dc.subject.otherHumansen
dc.subject.otherHydroxyproline.urineen
dc.subject.otherMaleen
dc.subject.otherMuscles.drug effects.physiologyen
dc.subject.otherOsteocalcin.blooden
dc.subject.otherParathyroid Hormone.blooden
dc.subject.otherPhosphates.blooden
dc.subject.otherRegression Analysisen
dc.subject.otherSerum Albumin.analysisen
dc.subject.otherTestosterone.analogs & derivatives.blood.pharmacokinetics.pharmacologyen
dc.titleBody composition and muscle strength in healthy men receiving testosterone enanthate for contraception.en
dc.typeJournal Articleen
dc.identifier.journaltitleThe Journal of Clinical Endocrinology and Metabolismen
dc.identifier.affiliationUniversity of Melbourne, Department of Endocrinology, Austin Hospital, Victoria, Australiaen
dc.identifier.doi10.1210/jcem.77.4.8408450en
dc.description.pages1028-32en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/8408450en
dc.type.austinJournal Articleen
local.name.researcherSeeman, Ego
item.openairetypeJournal Article-
item.cerifentitytypePublications-
item.grantfulltextnone-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.languageiso639-1en-
crisitem.author.deptEndocrinology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

26
checked on Nov 25, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.